Expert Ratings For Nevro
Within the last quarter, Nevro (NYSE:NVRO) has observed the following analyst ratings:
Recap: Nevro Q4 Earnings
Nevro (NYSE:NVRO) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Earnings
Nevro reported in-line EPS of $-0.86 versus an estimate of $-0.86.
Nevro Q4 EPS $(0.86), Inline, Sales $102.80M Beat $100.26M Estimate
Nevro (NYSE:NVRO) reported quarterly losses of $(0.86) per share which met the analyst consensus estimate. This is a 309.52 percent decrease over losses of $(0.21) per share from the same period last year. The company
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
Here's a roundup of top developments in the biotech space over the last 24 hours.
Stocks In Focus
Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase 2b/3 Study
Earnings Scheduled For February 23, 2022
Companies Reporting Before The Bell
• Sapiens Intl Corp (NASDAQ:SPNS) is likely to report earnings for its fourth quarter.
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.
Nevro Responds To Competitor’s Announcement Of FDA Approval For Painful Diabetic Neuropathy
Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today responded to Medtronic's announcement of FDA approval
Truist Securities Maintains Hold on Nevro, Lowers Price Target to $95
Truist Securities maintains Nevro (NYSE:NVRO) with a Hold and lowers the price target from $105 to $95.
